T cells for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized treatment using your own immune cells (T cells) that are specially trained to find and attack lung cancer cells. It may help people with advanced or relapsed lung cancer who have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III, IV, or relapsed lung cancer confirmed by biopsy.
- You are between 18 and 80 years old.
- At least 4 weeks have passed since your last chemotherapy or radiation, and at least 2 weeks since steroids or other immune-suppressing drugs.
- Your cancer cells show high levels of specific markers (antigens) that the T cells can target.
- You are generally well enough to carry out daily activities (Karnofsky score of 50% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
This trial tests a new cell therapy called BST08, made from your own immune cells, for advanced non-small cell lung cancer that has not responded to at least two standard treatments. The goal is to see if this therapy is safe and can help shrink tumors.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.